Enterprise Value
44.16M
Cash
12.61M
Avg Qtr Burn
-6.76M
Short % of Float
4.99%
Insider Ownership
64.47%
Institutional Own.
4.45%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TTP399 (GLP-1R agonists) Details Type 1 diabetes, Diabetes | Phase 3 Initiation | |
HPP737 (PDE4 inhibitor) Details Psoriasis, Skin disease/disorder | Phase 2 Update | |
TTP399 (GLP-1R agonists) Details Diabetes, Type 2 diabetes | Phase 2 Initiation | |
TTP273 (Oral GLP-1R) Details Diabetes, Type 2 diabetes, Cystic fibrosis | Phase 1/2 Update | |
TTP488 (Azeliragon) (RAGE) Details Frontotemporal dementia with C9orf72 mutation, Dementia, Alzheimer's disease, Neurological disorder | Failed Discontinued |